Miach Orthopaedics

Executive Summary

Miach Orthopaedics is a pioneering medical device company focused on bio-enhanced implants for orthopedic soft tissue repair. Its flagship product, the BEAR Implant, is the first and only FDA-approved medical technology that enables the body to heal a torn anterior cruciate ligament (ACL) by using a bovine-derived collagen scaffold to bridge the torn ends, thereby restoring the native ligament. This innovation represents a paradigm shift in ACL reconstruction, offering patients the potential to avoid the morbidity associated with autograft harvest or the risks of allograft use. The BEAR Implant has already been used in thousands of procedures and continues to gain adoption among orthopedic surgeons. The company's market opportunity is substantial, with over 200,000 ACL reconstructions performed annually in the U.S. alone. Miach's technology platform has the potential to extend beyond ACL repair to address other soft tissue injuries, such as rotator cuff tears or meniscal repair, significantly expanding its addressable market. With a strong intellectual property portfolio and early commercial traction, Miach Orthopaedics is well-positioned for growth. Key upcoming milestones include the publication of long-term clinical data and expansion into international markets.

Upcoming Catalysts (preview)

• Q2 2026Publication of 5-year follow-up data from BEAR Implant pivotal study80% success
• Q4 2026FDA approval for expanded indication (partial ACL tears)40% success
• Q3 2026Strategic partnership for Asia-Pacific distribution50% success